[11 cases of neuropathy induced by almitrine, of which one had optic neuropathy].
The only etiologic factor retained in 11 patients with sensory or sensory-motor neuropathy was almitrine therapy. In one patient there was in addition an optic neuropathy. The reduction in visual acuity in this patient coincided with the onset of the sensory-motor neuropathy of lower limbs after treatment with 100 mg/day of almitrine over a 2-year period. No other metabolic, inflammatory, toxic, vascular or immunologic cause was found. There was a moderate chronic respiratory insufficiency. Visual recuperation started one month after the arrest of almitrine treatment and was satisfactory 7 months later. The other 10 patients had neuropathy of limbs without visual disorders. Neuromuscular biopsy in one case showed lesions to be of the axonal type.
D000368:Aged; D015765:Almitrine; D001369:Axons / Q000648:ultrastructure; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D004594:Electrophysiology; D005074:Evoked Potentials, Visual / Q000187:drug effects; D005260:Female; D006801:Humans; D007866:Leg / Q000294:innervation; D008297:Male; D008875:Middle Aged; D009902:Optic Neuritis / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D010879:Piperazines / Q000009:adverse effects*; D014785:Vision, Ocular / Q000187:drug effects
D000697:Central Nervous System Stimulants; D010879:Piperazines; D015765:Almitrine
Onze cas de neuropathie à l'almitrine, dont un avec neuropathie optique.